167 related articles for article (PubMed ID: 33824096)
1. Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis.
Chi C; Fan L; Dong B; Zhu Y; Xin Z; Pan J; Xue W
Clin Genitourin Cancer; 2021 Aug; 19(4):e223-e234. PubMed ID: 33824096
[TBL] [Abstract][Full Text] [Related]
2. Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis.
Narita S; Nara T; Kanda S; Numakura K; Saito M; Inoue T; Satoh S; Nanjo H; Tsuchiya N; Mitsuzuka K; Koie T; Kawamura S; Ohyama C; Tochigi T; Arai Y; Habuchi T
Clin Genitourin Cancer; 2019 Feb; 17(1):e113-e122. PubMed ID: 30391137
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
Thalgott M; Horn T; Heck MM; Maurer T; Eiber M; Retz M; Autenrieth M; Herkommer K; Krause BJ; Gschwend JE; Treiber U; Kübler HR
J Hematol Oncol; 2014 Mar; 7():20. PubMed ID: 24598155
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
Zhao X; Xiao YT; Yang Y; Ye Y; Chang Y; Jiang L; Eftekhar M; Ren S; Zhang H
Cancer Control; 2022; 29():10732748221120462. PubMed ID: 35980734
[TBL] [Abstract][Full Text] [Related]
6. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial.
Dai B; Zhang S; Wan FN; Wang HK; Zhang JY; Wang QF; Kong YY; Ma XJ; Mo M; Zhu Y; Qin XJ; Lin GW; Ye DW
Eur Urol Oncol; 2022 Oct; 5(5):519-525. PubMed ID: 35780048
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemohormonal Therapy in Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis.
Ge Q; Xu H; Yue D; Fan Z; Chen Z; Xu J; Zhou Y; Zhang S; Xue J; Shen B; Wei Z
Front Oncol; 2022; 12():906370. PubMed ID: 35646683
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer.
Sasaki T; Nishikawa K; Kato M; Masui S; Yoshio Y; Sugimura Y; Inoue T
Med Sci (Basel); 2021 Apr; 9(2):. PubMed ID: 33918590
[TBL] [Abstract][Full Text] [Related]
9. Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.
Enokida H; Yamada Y; Tatarano S; Yoshino H; Yonemori M; Sakaguchi T; Nishimura H; Eura R; Nakagawa M
Jpn J Clin Oncol; 2020 Jan; 50(1):66-72. PubMed ID: 31665352
[TBL] [Abstract][Full Text] [Related]
10. Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy.
Oishi T; Hatakeyama S; Tabata R; Fujimori D; Fukuda M; Shinozaki T; Ishii N; Iwamura H; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Sato S; Ohyama C
Sci Rep; 2023 Mar; 13(1):3436. PubMed ID: 36859718
[TBL] [Abstract][Full Text] [Related]
11. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.
Meyer F; Bairati I; Bédard C; Lacombe L; Têtu B; Fradet Y
Urology; 2001 Aug; 58(2 Suppl 1):71-7. PubMed ID: 11502453
[TBL] [Abstract][Full Text] [Related]
12. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
Eastham JA; Heller G; Halabi S; Monk JP; Beltran H; Gleave M; Evans CP; Clinton SK; Szmulewitz RZ; Coleman J; Hillman DW; Watt CR; George S; Sanda MG; Hahn OM; Taplin ME; Parsons JK; Mohler JL; Small EJ; Morris MJ
J Clin Oncol; 2020 Sep; 38(26):3042-3050. PubMed ID: 32706639
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
Roach M; DeSilvio M; Lawton C; Uhl V; Machtay M; Seider MJ; Rotman M; Jones C; Asbell SO; Valicenti RK; Han S; Thomas CR; Shipley WS;
J Clin Oncol; 2003 May; 21(10):1904-11. PubMed ID: 12743142
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.
McClintock TR; von Landenberg N; Cole AP; Lipsitz SR; Gild P; Sun M; Fletcher SA; Roghmann F; Menon M; Nguyen PL; Noldus J; Choueiri TK; Kibel AS; Trinh QD
Ann Surg Oncol; 2019 Jan; 26(1):297-305. PubMed ID: 30430324
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer.
Fan J; Liang H; Gu Y; Jiang Z; Jiang F; Wang Y; He D; Wu K
Urol Oncol; 2023 Aug; 41(8):354.e1-354.e9. PubMed ID: 37295981
[TBL] [Abstract][Full Text] [Related]
16. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
17. CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.
Sheikhbahaei S; Reyes DK; Rowe SP; Pienta KJ
Prostate; 2021 Feb; 81(2):127-134. PubMed ID: 33259087
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemohormonal therapy followed by robot-assisted and minimum incision endoscopic radical prostatectomy in patients with high-risk prostate cancer: comparison of perioperative and oncological outcomes at single institution.
Fujita N; Koie T; Hashimoto Y; Narita T; Tobisawa Y; Tanaka T; Noro D; Oikawa M; Hagiwara K; Yoneyama T; Imai A; Yamamoto H; Hatakeyama S; Yoneyama T; Ohyama C
Int Urol Nephrol; 2018 Nov; 50(11):1999-2005. PubMed ID: 30229466
[TBL] [Abstract][Full Text] [Related]
19. The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
Wang Y; Wu G; Fan L; Pan J; Gong Y; Fei X; Du X; Zhu Y; Xue W
Prostate; 2021 Jun; 81(8):463-468. PubMed ID: 33822399
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]